Joë-Marc Chauvin

Also affiliated with University of Pittsburgh Medical Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial”.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

TIGIT in cancer immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000957

N/A

0.992DataRank · unranked

744 citations

Hassane M. Zarour, Joë-Marc Chauvin

Targeting novel inhibitory receptors in cancer immunotherapy

Seminars in Immunology(2020)10.1016/j.smim.2020.101436

N/A

0DataRank · unranked

15 citations

Joë-Marc Chauvin, Hassane M. Zarour, Quanquan Ding

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Nature Medicine(2022)10.1038/s41591-022-01698-2

N/A

0DataRank · unranked

445 citations

Diwakar Davar, Richard R. Rodrigues, Jonathan H. Badger, Jennifer R. Fang, Alicia M. Cole +26 more

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Journal of Clinical Investigation(2022)10.1172/jci152864

N/A

0DataRank · unranked

69 citations

Robert M. Morrison, Joë-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding +28 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0575

N/A

0DataRank · unranked

146 citations

Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio +11 more